NVS vs AZN Stock Comparison

Novartis Ag and Astrazeneca Prices as of Nov 13, 2026 Peers: Industry group
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$306.35B
P/E
17.9x
Revenue (TTM)
—
Div. yield
2.95%
Pharmaceuticals Healthcare
7 wins
AZN Astrazeneca Plc
$184.49 +13.8% 1M +4.1% 1Y
Market cap
$285.96B
P/E
25.9x
Revenue (TTM)
$59.37B
Div. yield
1.30%
Pharmaceuticals Healthcare

Head to Head

7 decided of 12

Novartis Ag leads on 7 of the 12 questions below (Novartis Ag 7). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNVSAZNLeader
Larger companyMarket capitalisation $306.35B $285.96B NVS
Cheaper on earningsLower P/E, profitable companies only 17.9x 25.9x NVS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.1x 18.4x NVS
Faster revenue growthRevenue growth, trailing twelve months — +7.8% –
More profitableNet margin, trailing twelve months — 18.6% –
Better return on capitalReturn on invested capital — 23.1% –
Less leveragedLower net debt / EBITDA — -0.7x –
Higher dividend yieldTrailing dividend yield 2.95% 1.30% NVS
Better 1-year returnPrice return, last 12 months +21.7% +4.1% NVS
Better 5-year returnAnnualised price return, 5 years +14.3%/yr +9.4%/yr NVS
Less volatileAnnualised volatility, 1 year 27.8% 28.1% NVS
Higher overall scoreMean of the five percentile scores vs peers — 74/100 –

Percentile Scorecard

NVSAZN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNVSAZN
Valuation 96 #26 of 660 85 #102 of 660
Growth – 57 #268 of 619
Profitability – 94 #36 of 595
Financial Health – 65 #237 of 683
Shareholder Returns 79 #97 of 459 67 #151 of 459
Overall – 74
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • AZN ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNVSAZNSPY
1 month +9.3%+13.8% -2.0%
3 months +6.4%+17.9% -2.8%
6 months +8.4%+1.6% +2.0%
Year to date +16.5%+0.3% +10.6%
1 year +21.7%+4.1% +12.2%
3 years +69.2%+43.6% +68.1%
3 years, per year +19.2%+12.8% +18.9%
5 years +94.6%+56.9% +61.4%
5 years, per year +14.3%+9.4% +10.1%
10 years +118.5%+229.7% +248.5%
10 years, per year +8.1%+12.7% +13.3%

Risk

MeasureNVSAZNSPY
Volatility, 1Y 27.8%28.1% 13.6%
Downside volatility, 1Y 30.0%26.9% 13.9%
Beta vs S&P 500, 1Y 0.360.19 1.00
Return / volatility, 1Y 0.780.15 0.90
Max drawdown, 5Y -20.4%-27.9% -25.4%
From 52-week high -4.8%-11.9% -3.2%
52-week high $168.62$209.48 $779.14
52-week low $124.36$155.60 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNVSAZN
P/E now vs peer median 17.9xmedian 17.0x 25.9xmedian 17.0x
P/S now vs peer median 5.1xmedian 8.4x 4.8xmedian 8.4x
EV/EBITDA now vs peer median —median 14.6x 12.8xmedian 14.6x
P/FCF now vs peer median 14.3xmedian 19.0x 26.9xmedian 19.0x
P/B now vs peer median —median 2.0x 5.5xmedian 2.0x
PEG now vs peer median —median 0.43 1.12median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNVSAZN
Revenue – $59.37B
Gross profit – $51.12B
Operating income – $14.78B
Net income – $11.03B
Free cash flow – $10.63B
R&D – $15.30B
EPS (diluted) – $7.06
Cash & equivalents $400.00M $7.94B
Total debt – -$6.68B
Shares (diluted) 1.96B 1.56B
Enterprise value $279.93B $259.56B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNVSAZN
P/E 17.9x 25.9x
P/FCF 14.3x 26.9x
P/Operating cash flow – 21.6x
P/S 5.1x 4.8x
P/B – 5.5x
P/Tangible book – 20.9x
EV/EBITDA – 12.8x
EV/EBIT – 18.3x
EV/Revenue – 4.6x
EV/FCF – 25.5x
EV/Operating cash flow – 20.5x
PEG (3Y EPS CAGR) – 1.12

Growth

14 metrics
MetricNVSAZN
Revenue growth (1Y) – 7.8%
Revenue CAGR (3Y) – 10.3%
Gross profit growth (1Y) – 6.7%
Gross profit CAGR (3Y) – 12.3%
Operating income growth (1Y) – 15.4%
Operating income CAGR (3Y) – 22.6%
Net income growth (1Y) – 17.3%
Net income CAGR (3Y) – 23.2%
EPS growth (1Y) – 17.5%
EPS CAGR (3Y) – 23.2%
Operating cash flow growth (1Y) – -12.6%
Operating cash flow CAGR (3Y) – –
Free cash flow growth (1Y) – -22.8%
Free cash flow CAGR (3Y) – –

Profitability

14 metrics
MetricNVSAZN
Gross margin – 86.1%
EBITDA margin – 35.7%
Operating margin – 24.9%
Pretax margin – 22.4%
Net margin – 18.6%
FCF margin – 17.9%
Operating cash flow margin – 22.3%
Return on equity – 21.6%
Return on assets – 9.4%
Return on invested capital – 23.1%
Return on capital employed – 9.9%
Asset turnover – 0.5x
Cash conversion (OCF / net income) – 1.2x
Stock comp / revenue – –

Financial Health

11 metrics
MetricNVSAZN
Debt / assets – -5.6%
Debt / equity – -0.1x
Net debt / EBITDA – -0.7x
Debt / FCF – -0.6x
Liabilities / assets – 56.8%
Equity / assets – 43.2%
Interest coverage – 16.1x
Current ratio – -1.0x
Quick ratio – -0.8x
Cash ratio – -0.3x
Altman Z-score – 4.21

Shareholder Returns

7 metrics
MetricNVSAZN
Dividend yield 3.0% 1.3%
Net buyback yield – 0.0%
Shareholder yield 3.0% 1.3%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNVSAZN
Forward P/E 17.1xFY2026 18.4xFY2026
EPS, next fiscal year $9.38FY2026 $10.00FY2026
EPS growth, next FY +4.5%FY2026 +9.2%FY2026
EPS growth, the year after +0.9% +5.7%
Revenue, next fiscal year $53.97BFY2026 $58.85BFY2026
Revenue growth, next FY -1.0%FY2026 +0.2%FY2026
Revenue growth, the year after +19.3% +7.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNVSAZN
Held by institutions 7.0% 52.1%
Institutions holding 1,610 1,498
Change in shares held, QoQ -6.0% +7.8%
Institutions buying 662 809
Institutions selling 562 469
Buyers to sellers 1.18 1.72

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NVSAZN
NVS 1.00 0.56
AZN 0.56 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NVS and AZN?

Novartis Ag (NVS) is the largest by market capitalisation: Novartis Ag (NVS) $306.35B, Astrazeneca (AZN) $285.96B.

Which stock is cheaper, NVS and AZN?

Novartis Ag (NVS) trades on the lowest price-to-earnings ratio (Novartis Ag (NVS) 17.9x, Astrazeneca (AZN) 25.9x). On next year's consensus earnings, Novartis Ag (NVS) is cheapest (Novartis Ag (NVS) 17.1x, Astrazeneca (AZN) 18.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which stock has performed better?

Over the past year Novartis Ag (NVS) returned the most: Novartis Ag (NVS) +21.7%, Astrazeneca (AZN) +4.1%. Over five years, Novartis Ag (NVS) compounded fastest (Novartis Ag (NVS) +14.3%/yr, Astrazeneca (AZN) +9.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Novartis Ag (NVS) has the highest dividend yield: Novartis Ag (NVS) 2.95%, Astrazeneca (AZN) 1.30%.

Which stock is riskier?

By one-year price volatility, Novartis Ag (NVS) has been the steadiest (Novartis Ag (NVS) 27.8%, Astrazeneca (AZN) 28.1%). Volatility measures how widely the price swings, not the risk of the business.

Do NVS and AZN move together?

Their daily returns over the past year have a correlation of 0.56, a moderate positive relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, NVS and AZN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Novartis Ag (NVS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.